Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of E6011 in healthy Japanese men
NCT02146261Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2013
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of quetmolimab in Crohn's disease, rheumatoid arthritis (RA) and primary biliary cholangitis (PBC) (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Concentration up to 10 Weeks, Time to attain Cmax up to 10 Weeks and 6 more. Started Sep 2013; status: completed.
02
Drugs
quetmolimab
03
Conditions
Crohn's diseaserheumatoid arthritis (RA)primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02146261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02146261.